At Phibro’s anticoccidial product launch session at Phibro Animal Health, Poultry Gut Health and Coccidiosis Management Seminar, Dr. Serdar Ertas positioned coccidiosis as one of the most persistent drivers of performance loss in poultry production, not only due to clinical disease but also due to the heavy economic impact of subclinical pressure.

He explained that in broiler and turkey production, coccidiosis can reduce feed efficiency, impair growth, and disrupt flock uniformity. For Ertas, anticoccidial programs should be built not only to suppress disease but to protect gut health as a productivity asset. His warning was that even strong products fail when used without correct timing and program structure, and unplanned use accelerates resistance development.

Ertas also detailed Phibro’s anticoccidial portfolio and how different actives fit different field conditions. He referenced lasalocid, semduramicin, robenidine, and decoquinate as options designed to support varied production realities.

On lasalocid, he highlighted its broad spectrum and suitability under hot climate conditions, and noted its profile supports immune development.

On semduramicin, he described it as a “new generation ionophore,” emphasizing low-dose efficacy and performance benefits under high infection pressure.

On robenidine, he positioned it as helpful for “field cleaning,” particularly within shuttle programs for resistance management.

On decoquinate, he emphasized reliability, flexibility for longer use, and zero-day withdrawal as a practical advantage.

His closing line summarized his philosophy: sustainable success comes from scientific, field-fit programs and regular monitoring. “Coccidiosis management is not choosing a product,” he stated, “it is managing a strategy.”

In a separate interview focused on Turkiye, Ertas added historical context: he described how control approaches evolved from ingredient-focused practices toward system-based management from the mid-1990s onward, with gut health evaluation, lesion scoring, and performance analysis becoming central. He also pointed to regulatory and approval dynamics reshaping product use. His long-term view is that the future will rely increasingly on data analysis, flock-level evaluation, and preventive veterinary practices.